9/11 Skin Cancer Lawyers: VCF Compensation & WTC Health Program Benefits

Who qualifies for 9/11 skin cancer compensation?

Anyone diagnosed with skin cancer following presence in the covered 9/11 areas, at the Pentagon, or in Shanksville, Pennsylvania during the covered periods may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from 9/11-related skin cancer.

Free medical care runs through the WTC Health Program, which covers Manhattan south of Houston Street, routes of debris removal (responders only), and any block in Brooklyn within 1.5 miles of the former World Trade Center site. Compensation runs through the VCF, which covers Manhattan south of Canal Street plus routes of debris removal.

If you were between Canal and Houston Street, you may still qualify for both. Daily life in Lower Manhattan rarely stopped at Canal Street, and presence can be established with documentary proof and/or witness statements.

Non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) are among the most frequently certified cancers in the 9/11 community, reflecting both their high incidence in the general population and the extensive dust and debris skin contact that responders, cleanup workers, and downtown residents experienced in the weeks and months after September 11th.

What types of skin cancer are covered by the WTC Health Program?

The WTC Health Program certifies three principal types of skin cancer. Basal cell carcinoma and squamous cell carcinoma are grouped together as non-melanoma skin cancer, share one VCF award category, and are covered in full on this page. Melanoma sits in a different award category and has its own page.

42 C.F.R. §88.15(d)(13) lists "malignant neoplasms of the skin (melanoma and non-melanoma), including scrotal cancer" as a covered WTC-related health condition. Basal cell carcinoma and squamous cell carcinoma are both classified as non-melanoma skin cancers.

Basal cell carcinoma (BCC)

Basal cell carcinoma is the most common skin cancer and the most common cancer of any type in the United States, per American Cancer Society reference data. It arises from the basal cells at the bottom of the epidermis and rarely spreads to other parts of the body.

Untreated, BCC can grow deep into surrounding tissue. On the face it can reach cartilage and bone, and in rare cases it spreads along nearby nerves. That local tissue damage, rather than metastasis, is the main medical concern. The common subtypes are:

• Nodular: the most common subtype, per American Cancer Society reference data. A pearly, waxy bump, often with visible blood vessels, most often on the face, ears, and neck.
• Superficial: a flat, scaly, reddish or pinkish patch, most often on the trunk or shoulders. It is frequently mistaken for eczema or psoriasis before a biopsy.
• Morpheaform (sclerosing or infiltrative): grows into surrounding tissue with poorly defined borders and carries a higher risk of recurrence.
• Pigmented: contains melanin and can look like melanoma. A biopsy tells them apart.
• Basosquamous: a mixed pattern with features of both BCC and SCC, and more aggressive than typical BCC.

Squamous cell carcinoma (SCC)

Squamous cell carcinoma is the second most common skin cancer, per American Cancer Society reference data. It arises from the squamous cells in the outer layer of the epidermis and grows faster than BCC.

SCC is more likely than BCC to spread, particularly when it arises on the lip, ear, or scalp. People who are immunocompromised, including transplant recipients and those on long-term immunosuppression, carry a substantially higher risk of SCC and of more aggressive disease. The common subtypes and variants are:

• Well-differentiated: the most common presentation, with tumor cells that closely resemble normal squamous cells. Generally the most favorable outlook.
• Moderately and poorly differentiated: increasingly abnormal cells, with higher rates of recurrence and spread.
• Acantholytic (adenoid) and spindle cell (sarcomatoid): rarer variants that behave more aggressively than typical SCC.
• Verrucous carcinoma: a slow-growing, wart-like tumor. Locally destructive but rarely spreads.
• Keratoacanthoma-type: a fast-growing, dome-shaped lesion with a central keratin plug.
• Marjolin's ulcer: SCC that arises within a chronic wound, scar, or burn site.

For both BCC and SCC, the subtype and location shape the treatment and can affect economic loss. They do not move the claim out of the non-melanoma award category.

Melanoma

Melanoma is the most serious common skin cancer. It arises from melanocytes, the pigment-producing cells of the skin, and is far less common than BCC or SCC but accounts for the majority of skin cancer deaths, per American Cancer Society reference data. Its subtypes, staging, and award category are covered on the 9/11 melanoma claims page.

Rare skin cancers

Rare skin cancers, including Merkel cell carcinoma, dermatofibrosarcoma protuberans, cutaneous T-cell lymphoma (mycosis fungoides), Kaposi sarcoma, and sebaceous carcinoma, are evaluated case by case under the WTC Health Program's rare-cancer certification framework.

More than 400,000 people are estimated to have been exposed to 9/11 toxins in Lower Manhattan alone, with additional exposures at the Pentagon and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens including asbestos, silica, polycyclic aromatic hydrocarbons, dioxins, furans, heavy metals, and other combustion byproducts.

Skin was one of the most directly exposed organs. Dust settled on the face, neck, forearms, and any uncovered surface, and prolonged contact was the norm for responders, cleanup workers, and residents returning to Lower Manhattan.

Skin cancer arises through cumulative damage to skin cell DNA. Ultraviolet radiation is the most well-established environmental cause of skin cancer, but chemical carcinogens, including several of those documented in the 9/11 dust, also contribute. Polycyclic aromatic hydrocarbons and arsenic, both present in the WTC debris field, have long been recognized as chemical carcinogens with a documented association with non-melanoma skin cancer.

Skin cancer does not appear immediately after exposure to a carcinogen. There is typically a period of years between exposure and clinical detection. The WTC Health Program requires a minimum four-year latency period between first 9/11 exposure and first skin cancer diagnosis before certification.

Certification does not require proof that 9/11 exposure was the only cause of a particular skin cancer. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition. Fair skin, cumulative sun exposure, prior tanning bed use, family history, and other established skin cancer risk factors are common in the 9/11 community and generally do not prevent certification.

Skin cancer symptoms vary by type. Most basal and squamous cell carcinomas appear on sun-exposed skin: the face, ears, lips, scalp, neck, forearms, and backs of the hands. Early lesions are rarely painful, which is why many go unaddressed until they grow, bleed, or fail to heal.

Basal cell carcinoma signs

• A pearly, waxy, or translucent bump with visible surface blood vessels, most common on the head and neck
• A flat, scaly, reddish or pinkish patch on the trunk or shoulders that does not resolve
• A shiny, flesh-colored or pale scar-like area with poorly defined borders
• A raised, rolled border around a central depression or ulceration
• A sore that heals and then returns, or bleeds without an obvious cause

Squamous cell carcinoma signs

• A firm, red nodule, or a flat lesion with a scaly, crusted surface
• A sore that ulcerates and does not heal
• A rough, scaly patch on the lip that cracks or bleeds
• A wart-like growth that crusts and may bleed
• A new sore or raised area within an old scar, burn, or chronic wound
• Rough, scaly patches (actinic keratoses), which are precancerous and can progress to squamous cell carcinoma

Melanoma signs

Melanoma is usually identified with the ABCDE rule: asymmetry, irregular borders, uneven color, a diameter larger than about 6 millimeters, and a mole that changes over time. The full warning signs are on the melanoma page.

Early detection matters most for melanoma and for squamous cell carcinoma at high-risk sites, both of which are far more dangerous once they spread. Enrolled WTC Health Program members are evaluated by the program's participating providers, who handle the biopsy and pathology records that certification relies on.

The WTC Health Program requires a minimum four-year latency period between the first date of 9/11 exposure and first date of skin cancer diagnosis. This latency requirement is set by the WTC Health Program and applies to basal cell carcinoma, squamous cell carcinoma, and melanoma. A skin cancer diagnosed less than four years after first date of exposure cannot be certified as 9/11-related.

Most skin cancer claimants meet the four-year requirement on its face. If the first 9/11 exposure occurred in September 2001 or in the weeks and months following, skin cancers diagnosed from that same date in September 2005 forward satisfy latency. Diagnoses from 2010, 2015, or 2020 are all well past the latency threshold.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the skin cancer as 9/11-related, not from the date of diagnosis. Registration preserves the right to file a claim; the actual claim filing deadline is October 1, 2090 for all claimants. A skin cancer diagnosed years ago remains eligible for certification.

What is the VCF payout for 9/11 skin cancer?

Certified 9/11 skin cancer qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the VCF. The VCF's non-economic loss awards for skin cancer depend on the type.

The $250,000 single-cancer and $90,000 single non-cancer maximums are caps set under the VCF Act. Amounts within them are set by VCF policy, which the VCF revises over time.

Non-economic loss awards by skin cancer type

• Non-melanoma skin cancer (basal cell and squamous cell): typically $90,000. VCF Policies & Procedures Section 2.1 names non-melanoma skin cancer at this level. It is one category: a certified BCC, a certified SCC, or both on the same claim fall within the same award.
• Melanoma baseline: $250,000. Melanoma is compensated at the statutory maximum for a single cancer condition, reflecting its significantly higher mortality and risk of metastasis.
• Both a non-melanoma skin cancer and a melanoma. In the firm's experience, claims with both certified generally reach about $300,000 combined. The VCF does not publish this figure. It is a pattern the firm sees, not a stated rule.
• Skin cancer alongside other certified conditions. VCF policy figures reach about $340,000 for certain combinations of multiple cancers, or a cancer combined with severe lung disease. That is the highest amount current VCF policy allows for noneconomic loss (pain and suffering) and in the firm's experience, awards at that level are rare.

Multiple non-melanoma skin cancers

Many claimants develop more than one basal cell or squamous cell carcinoma over the years. The non-melanoma framework is condition-based rather than lesion-based, so several BCCs, several SCCs, or a mix of both fall within the one non-melanoma award rather than receiving a separate award for each lesion.

The full history still matters for the medical record and for economic loss. For how multiple diagnoses and a later melanoma affect an existing award, see the post on whether multiple skin cancers raise a VCF award.

Metastatic or recurrent skin cancer

Squamous cell carcinoma that has spread to the lymph nodes or beyond, and basal cell carcinoma that has invaded cartilage, bone, or nerves, are more serious than a routine excision. The non-melanoma award category still applies to a single non-melanoma condition.

In the firm's experience, an award above the $90,000 level for non-melanoma skin cancer is uncommon. It generally takes a medical record showing frequent recurrences, metastasis, or permanent complications, and is usually pursued through a compensation appeal.

Economic loss and wrongful death compensation

Awards can also include economic loss, such as lost earnings, qualified out-of-pocket medical expenses, and wrongful death compensation in fatal cases.

Treatment that commonly adds to the economic record includes Mohs surgery on the face or lip, reconstruction after an extensive excision, treatment of morpheaform or recurrent lesions, lymph node dissection, radiation, or immunotherapy for advanced SCC, and repeated procedures over many years.

Wrongful death compensation is available to the personal representatives of individuals who died from 9/11-related skin cancer. Most skin cancer deaths involve melanoma, but aggressive or metastatic squamous cell carcinoma, and rarely basal cell carcinoma, can also be fatal.

How Baione Law handles a 9/11 skin cancer claim

Baione Law represents 9/11 skin cancer claimants at every stage:

1. Free Case Review. The firm evaluates presence in the exposure zone, exposure category, skin cancer diagnosis and type (BCC, SCC, melanoma, or rare skin cancer), and current WTC Health Program certification status. No cost, no obligation.
2. Our fee is 10%, paid only from your award. If you don't get paid, neither do we. The 10% cap is set by federal statute.
3. WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates dermatology and pathology record submission to WTC Health Program medical providers for certification, including for the full history of skin cancer diagnoses.
4. VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, pathology, and treatment history.
5. Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires, particularly where a claimant has multiple certified skin cancers, metastatic disease, or a skin cancer alongside other certified conditions.
6. Award, appeals, and amendments. After the VCF issues an award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions, including a later melanoma or the certification of additional non-melanoma skin cancers.